Christopher Frankenfield
2023
In 2023, Christopher Frankenfield earned a total compensation of $1.9M as Chief Operating Officer at Xilio Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $210,000 |
|---|---|
| Option Awards | $1,156,022 |
| Salary | $481,108 |
| Other | $13,740 |
| Total | $1,860,870 |
Frankenfield received $1.2M in option awards, accounting for 62% of the total pay in 2023.
Frankenfield also received $210K in non-equity incentive plan, $481.1K in salary and $13.7K in other compensation.
Rankings
In 2023, Christopher Frankenfield's compensation ranked 564th out of 2,647 executives tracked by ExecPay. In other words, Frankenfield earned more than 78.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 564 out of 2,647 | 79th |
Division Manufacturing | 322 out of 1,447 | 78th |
Major group Chemicals And Allied Products | 226 out of 817 | 72nd |
Industry group Drugs | 223 out of 783 | 72nd |
Industry Pharmaceutical Preparations | 139 out of 555 | 75th |
Source: SEC filing on April 25, 2024.
Frankenfield's colleagues
We found three more compensation records of executives who worked with Christopher Frankenfield at Xilio Therapeutics in 2023.